Cas no 5593-20-4 (Betamethasone dipropionate)

Betamethasone dipropionate is a synthetic corticosteroid with potent anti-inflammatory, antipruritic, and vasoconstrictive properties. It is commonly used in dermatological formulations to treat inflammatory skin conditions such as eczema, psoriasis, and dermatitis. The dipropionate ester enhances lipophilicity, improving skin penetration and prolonging localized activity while minimizing systemic absorption. Its high glucocorticoid receptor affinity ensures effective suppression of inflammatory mediators, reducing erythema, swelling, and itching. The compound is stable in topical preparations, including creams, ointments, and lotions, and is often preferred for its balanced efficacy-to-safety profile when used as directed. Proper dosing and application are critical to avoid potential adverse effects associated with prolonged corticosteroid use.
Betamethasone dipropionate structure
Betamethasone dipropionate structure
Product Name:Betamethasone dipropionate
CAS No:5593-20-4
MF:C28H37FO7
MW:504.587592840195
MDL:MFCD00072035
CID:46034
PubChem ID:87560009
Update Time:2025-11-11

Betamethasone dipropionate Chemical and Physical Properties

Names and Identifiers

    • betamethasone 17,21-dipropionate
    • BETA METHASONE DIPROPIONATE
    • BETAMETHASONE 17,21-DI-PROPIONATE
    • BETAMETHASONE 17-ALPHA,21-DIPROPIONATE
    • 1,4-PREGNADIEN-9-ALPHA-FLUORO-16-BETA-METHYL-11-BETA, 17,21-TRIOL-3,20-DIONE 17,21-DIPROPIONATE
    • 9ALPHA-FLUORO-16BETA-METHYL-11BETA,17ALPHA,21-TRIHYDROXY-1,4-PREGNADIENE-3,20-DIONE 17,21-DIPROPIONATE
    • 9a-fluoro-16b-methyl-11b,17a,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate
    • diproderm
    • diprolene
    • diprosis
    • diprosone
    • 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(propionate)
    • Betanmethasone Dipronate
    • Pregna-1,4-Diene-3,20-Dione,9-Fluoro-11-Hydroxy-16-Methyl-17,21-Bis(1-Oxopropoxy)-,(11Beta,16Beta)- (11-beta,16-beta)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate
    • Betamethasonediproprionate
    • 9--Fluoro-16--methyl-11,17,21-trihydroxy-1,4-pregnadiene-3,20-dione17,21-dipropionate
    • BETANMETHASONE DIPROPIONATE
    • BETAMETHASONEDIPROPIONATE,MICRONIZEDPOWDER,USP
    • Diprophos
    • Maxivate
    • Betamethaasone Dipropionate
    • Betamethasone
    • Psorion
    • Rinderon DP
    • S 3440
    • 9α-Fluoro-11β,17α,21-trihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate
    • Betamethasone dipropionate
    • Diprolene AF
    • Alphatrex
    • Sch 11460
    • CIWBQSYVNNPZIQ-XYWKZLDCSA-N
    • 826Y60901U
    • 1-Boc-3-piperidone
    • BETAMETHASONE DIPROPIONATE [VANDF]
    • Rinderon-DP
    • DTXCID302672
    • (11.beta.,16.beta.)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
    • 9-fluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate
    • DTXSID2022672
    • Pregna-1,4-diene-3,20-dione, 9-fluoro-11-.beta.,17,21-trihydroxy-16-.beta.-methyl-,17,21-dipropionate
    • Sch-11460
    • BETAMETHASONE DIPROPIONATE, AUGMENTED
    • BDBM50421892
    • betamethasone-dipropionate
    • .beta.-Methasone 17,21-dipropionate
    • NCGC00159443-02
    • S-3440
    • BRN 3638108
    • 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
    • component of Alphatrex (Salt/Mix)
    • Betamethasone-17,21-dipropionate
    • BETAMETHASONE DIPROPIONATE [USP-RS]
    • 9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene- 17,21-diyl dipropionate
    • Rinderon-DP (TN)
    • ENSTILAR COMPONENT BETAMETHASONE DIPROPIONATE
    • BETAMETHASONE DIPROPIONATE [USAN]
    • Betamethasone (as dipropionate)
    • BETAMETHASONE DIPROPIONATE [MART.]
    • Sernivo
    • BETAMETHASONE DIPROP
    • TACLONEX COMPONENT BETAMETHASONE DIPROPIONATE
    • WYNZORA COMPONENT BETAMETHASONE DIPROPIONATE
    • HY-13571
    • component of Betasone (Salt/Mix)
    • [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
    • Sernivo (TN)
    • CHEBI:31276
    • BETAMETHASONE DIPROPIONATE [GREEN BOOK]
    • CCG-269732
    • BETAMETHASONE DIPROPIONATE (EP MONOGRAPH)
    • BETAMETHASONE DIPROPIONATE [ORANGE BOOK]
    • NS00005151
    • Betamethasone dipropionate (USAN:USP:JAN)
    • LEO-90100 COMPONENT BETAMETHASONE DIPROPIONATE
    • 9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
    • D01637
    • s1688
    • Betamethasone dipropionate [USAN:USP:JAN]
    • 2-((2S,10S,11S,13S,15S,17S,1R,14R)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxo -14-propanoyloxytetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl)-2-o xoethyl propanoate
    • B3166
    • 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate
    • BETAMETHASONE DIPROPIONATE (USP-RS)
    • (11-beta,16-beta)-9-Chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
    • BETAMETHASONE DIPROPIONATE (USP MONOGRAPH)
    • 9-Fluoro-11.beta.-hydroxy-16.beta.-methyl-3,20-dioxo-17-(propionyloxy)pregna-1,4-dien-21-yl propionate #
    • AB01274713-01
    • BETAMETHASONE DIPROPIONATE [JAN]
    • NCGC00159443-01
    • BETAMETHASONE DIPROPIONATE COMPONENT OF WYNZORA
    • UNII-826Y60901U
    • 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate
    • Betamethasone Dipropionate USP, 0.05%
    • (11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate
    • CAS-5593-20-4
    • AKOS015969733
    • KS-5303
    • LOTRISONE COMPONENT BETAMETHASONE DIPROPIONATE
    • Diprospan
    • BRD-K58148589-001-03-6
    • BETAMETHASONE DIPROPIONATE [USP MONOGRAPH]
    • CHEMBL1200384
    • Betamethasone dipropionate (JP17/USP)
    • BETAMETHASONE DIPROPIONATE COMPONENT OF TACLONEX
    • Pregna-1,4-diene-3,20-dione,9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11b,16b)-
    • BETAMETHASONE 17.ALPHA.,21-DIPROPIONATE
    • AB01274713_02
    • Q4897349
    • BETAMETHASONE DIPROPIONATE COMPONENT OF ENSTILAR
    • AMY22130
    • Betamethasone-17,21-dipropionate 100 microg/mL in Acetonitrile
    • beta-Methasone 17,21-dipropionate
    • Betamethasone DipropionateAugmented
    • BETAMETHASONE DIPROPIONATE [WHO-DD]
    • BETAMETHASONE 17,21-DIPROPIONATE [MI]
    • PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11-HYDROXY-16-METHYL-17,21-BIS(1-OXOPROPOXY)-, (11.BETA.,16.BETA.)
    • CS-7549
    • Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)-
    • Tox21_113343
    • EINECS 227-005-2
    • BETAMETHASONE DIPROPIONATE [EP MONOGRAPH]
    • Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 17,21-dipropionate
    • NCGC00159360-02
    • BETAMETHASONE DIPROPIONATE COMPONENT OF LOTRISONE
    • Betamethasone Dipropionate (Diprolene)
    • NSC-758415
    • SCHEMBL7519
    • BETAMETHASONE DIPROPIONATE (MART.)
    • Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)
    • Diprolene (TN)
    • BETAMETHASONE DIPROPIONATE COMPONENT OF LEO-90100
    • 5593-20-4
    • NSC 758415
    • NCGC00159443-05
    • Betamethasone dipropionate (JP18/USP)
    • MDL： MFCD00072035
    • Inchi： 1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
    • InChI Key： CIWBQSYVNNPZIQ-XYWKZLDCSA-N
    • SMILES： F[C@@]12[C@]3(C=CC(C=C3CC[C@H]1[C@@H]1C[C@H](C)[C@](C(COC(CC)=O)=O)([C@@]1(C)C[C@@H]2O)OC(CC)=O)=O)C
    • BRN： 3638108

Computed Properties

  • Exact Mass: 504.25200
  • Monoisotopic Mass: 504.252
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 8
  • Heavy Atom Count: 36
  • Rotatable Bond Count: 8
  • Complexity: 1050
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 8
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 6
  • XLogP3: 3.6
  • Topological Polar Surface Area: 107

Experimental Properties

  • Color/Form: Powder
  • Density: 1.1481 (estimate)
  • Melting Point: 175.0 to 179.0 deg-C
  • Boiling Point: 622.9°C at 760 mmHg
  • Flash Point: 318.6°C
  • Refractive Index: 69 ° (C=1, Dioxane)
  • PSA: 106.97000
  • LogP: 3.81750
  • Solubility: Not determined
  • Merck: 1180
  • Specific Rotation: +66.0-+72.0° (c=1, Dioxane)

Betamethasone dipropionate Security Information

Betamethasone dipropionate Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
B123297-1g
Betamethasone dipropionate
 5593-20-4 ≥97.0%
1g
 ￥411.90 2023-09-04
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
B123297-5g
Betamethasone dipropionate
 5593-20-4 ≥97.0%
5g
 ￥1535.90 2023-09-04
S e l l e c k ZHONG GUO
S1688-500mg
Betamethasone Dipropionate
 5593-20-4 99.80%
500mg
 ￥795.01 2023-09-16
TRC
B327005-100mg
Betamethasone Dipropionate
 5593-20-4
100mg
 $ 68.00 2023-04-18
TRC
B327005-500mg
Betamethasone Dipropionate
 5593-20-4
500mg
 $ 121.00 2023-04-18
TRC
B327005-1g
Betamethasone Dipropionate
 5593-20-4
1g
 $ 164.00 2023-04-18
TRC
B327005-2.5g
Betamethasone Dipropionate
 5593-20-4
2.5g
 $ 215.00 2023-04-18
TRC
B327005-5g
Betamethasone Dipropionate
 5593-20-4
5g
 $ 270.00 2023-04-18
TRC
B327005-10g
Betamethasone Dipropionate
 5593-20-4
10g
 $ 368.00 2023-04-18
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R027663-1g
Betamethasone dipropionate
 5593-20-4 97%
1g
 ￥494 2023-07-11

Betamethasone dipropionate Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:5593-20-4)二丙酸倍他咪松
Order Number:LE26533625;LE2804;LE11929
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:55
Price ($):discuss personally
Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:5593-20-4)Betamethasone 17,21-dipropionate
Order Number:sfd8298
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:34
Price ($):discuss personally
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
(CAS:5593-20-4)Betamethasone 17,21-dipropionate
Order Number:LE213
Stock Status:in Stock
Quantity:5KG/1KG/25KG/100KG
Purity:99% HPLC
Pricing Information Last Updated:Thursday, 14 August 2025 14:44
Price ($):negotiated

Betamethasone dipropionate Spectrogram

1H NMR 300 MHz DMSO
1H NMR
13C NMR
13C NMR

Betamethasone dipropionate Related Literature

Related Categories

Additional information on Betamethasone dipropionate

Professional Introduction to Betamethasone Dipropionate (CAS No. 5593-20-4)

Betamethasone dipropionate, a synthetic corticosteroid, is widely recognized for its potent anti-inflammatory and immunosuppressive properties. With the chemical formula C28H42O6 and the CAS number 5593-20-4, this compound has become a cornerstone in the management of various inflammatory and autoimmune conditions. Its molecular structure, characterized by a fluorine atom at the 16th position, enhances its binding affinity to glucocorticoid receptors, making it highly effective in modulating the body's immune response.

The therapeutic applications of betamethasone dipropionate are extensive, ranging from topical treatments for skin disorders to systemic therapies for severe inflammatory conditions. One of its most notable uses is in the treatment of psoriasis, a chronic autoimmune disease characterized by rapid skin cell growth. Recent clinical trials have demonstrated that betamethasone dipropionate formulations, such as creams and ointments, can significantly reduce plaque formation and alleviate symptoms within weeks of treatment. This has made it a preferred choice for dermatologists managing moderate to severe cases of psoriasis.

In addition to its role in dermatology, betamethasone dipropionate has shown promise in osteoarthritis management. Studies have indicated that intra-articular injections of this compound can provide long-lasting pain relief by inhibiting pro-inflammatory cytokines and reducing synovial inflammation. A pivotal study published in the *Journal of Rheumatology* highlighted that patients receiving betamethasone dipropionate injections experienced a significant reduction in knee pain and improved functionality compared to placebo groups over a six-month period. This underscores the compound's potential as a non-pharmacological intervention for joint-related disorders.

The pharmacokinetic profile of betamethasone dipropionate is another critical aspect that contributes to its clinical efficacy. When administered topically, it exhibits high bioavailability due to its lipophilic nature, allowing for deep penetration into the skin layers. This property is particularly advantageous in treating conditions like eczema and psoriasis, where localized delivery is essential. Furthermore, systemic formulations of betamethasone dipropionate are designed to provide prolonged-release action, ensuring sustained therapeutic levels in the bloodstream. This has been particularly beneficial in managing conditions like asthma and rheumatoid arthritis, where consistent drug delivery is crucial for disease control.

Recent advancements in drug delivery systems have further enhanced the therapeutic potential of betamethasone dipropionate. Nanoparticle-based formulations have been explored as a means to improve drug solubility and target specificity. For instance, studies have shown that betamethasone dipropionate-loaded nanoparticles can enhance skin penetration and reduce systemic absorption, thereby minimizing side effects associated with long-term use. This innovation aligns with the growing trend toward personalized medicine, where tailored drug delivery systems can optimize therapeutic outcomes while reducing adverse effects.

The safety profile of betamethasone dipropionate is well-documented, with decades of clinical use providing a robust dataset on its efficacy and tolerability. However, like all corticosteroids, it is not without potential side effects. Prolonged use can lead to skin atrophy, hypothalamic-pituitary-adrenal (HPA) axis suppression, and increased susceptibility to infections. Therefore, healthcare providers must carefully balance the benefits and risks when prescribing this compound, particularly in pediatric populations and patients with comorbidities such as diabetes or osteoporosis.

In conclusion, betamethasone dipropionate (CAS No. 5593-20-4) remains a vital therapeutic agent in modern medicine due to its potent anti-inflammatory effects and broad spectrum of applications. The latest research continues to uncover new ways to leverage its benefits while mitigating risks through advanced drug delivery systems and personalized treatment approaches. As our understanding of inflammatory pathways evolves, betamethasone dipropionate is poised to play an even greater role in managing chronic inflammatory diseases worldwide.

5593-20-4 (Betamethasone dipropionate) Related Products

Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:5593-20-4)二丙酸倍他咪松
LE26533625;LE2804;LE11929
Purity:99%/99%/99%
Quantity:25KG,200KG,1000KG/25KG,200KG,1000KG/25KG,200KG,1000KG
Price ($):Inquiry/Inquiry/Inquiry
Email
Suzhou Senfeida Chemical Co., Ltd
(CAS:5593-20-4)Betamethasone 17,21-dipropionate
sfd8298
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email